

Neos Therapeutics, Inc. Announces the Appointment of Richard I. Eisenstadt as Chief Financial Officer

Dallas/Fort Worth, TX (May 22, 2014) - **Neos Therapeutics, Inc.** ("Neos" or "the Company"), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today the appointment of Richard I. Eisenstadt to the role of Chief Financial Officer, effective immediately.

Mr. Eisenstadt has over twenty-five years of finance leadership experience in the healthcare, life sciences and emerging technology industries. Before joining Neos Therapeutics, he served as Chief Financial Officer of ArborGen Inc., a leader in the development and commercialization of technologies that improve the productivity of trees. Prior to ArborGen, Mr. Eisenstadt was Vice President of Finance and Chief Financial Officer of Tranzyme Pharma (NASDAQ: TZYM), a drug discovery and development company, where he raised over \$100 million in both private and public equity and debt financings, including an initial public offering of the company's stock in April 2011.

Neos Therapeutics' President and Chief Executive Officer, Vipin Garg, stated, "I am excited to welcome Rich to the Neos team. He brings an extensive track record of finance and business experience and a broad understanding of funding and managing growth companies. Rich will work closely with the organization and financial community to ensure funding of our existing pipeline, and expansion of the use of our proprietary controlled release technologies to create additional CR orally disintegrating tablets and CR liquids to bring to market."

Prior to joining Tranzyme, Mr. Eisenstadt served as Director of Finance at Cogent Neuroscience, and held financial leadership positions at Nimbus CD International and Genicom Corporation.

Mr. Eisenstadt received his MBA from James Madison University and his BA in Economics from the University of North Carolina at Chapel Hill. He was the recipient of the Triangle Business Journal CFO of the Year award in 2011.

About ADHD

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioral disorder characterized by excessive levels of inattention and/or hyperactivity/impulsivity for an individual's age and level of development, which causes significant functional and social impairment. The disorder begins in childhood and up to 9.5% of children (ages 4-17) have received a diagnosis of ADHD (about 5.4 million school-aged children). For up to 50% of these individuals, the condition or symptoms of the condition persist into adulthood.

About Neos Therapeutics

Neos Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and manufacture of FDA approved drug products that utilize the Company's proprietary and patented delivery technologies. The Neos drug products are being developed using the Dynamic Time Release Suspension® (DTRS®) and Rapidly Disintegrating Ionic Masking!™ (RDIM!™) technologies that deliver

controlled release (CR) small molecule active pharmaceutical ingredients (APIs) in either liquid or oral disintegrating tablet (ODT) dosage forms. By utilizing APIs that are already FDA-approved, Neos can reduce development and regulatory risk and efficiently advance targeted proprietary Rx products through the FDA's New Drug Application (NDA) approval process. For more information, visit www.neostx.com.

Dynamic Time Release Suspension® and DTRS® are registered trademarks of Neos Therapeutics, LP, an affiliate of Neos Therapeutics, Inc., and Rapidly Disintegrating Ionic Masking™ and RDIM™ are trademarks of Neos Therapeutics, Inc.

This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.

CONTACTS

Vipin K. Garg, Ph.D.
Chief Executive Officer
(919) 434-6643
vgarg@neostx.com

Richard Eisenstadt, MBA
Chief Financial Officer
(972) 408-1389
reisenstadt@neostx.com

May 22, 2014